IP Library › Granted Patent US 9,701,657
Granted Patent B2
US 9,701,657 · App. 14/852,079 · Granted Jul 11, 2017

Histone demethylase inhibitors

Inventors: Toufike Kanouni (La Jolla, CA); Zhe Nie (San Diego, CA); Jeffrey Alan Stafford (San Diego, CA); James Marvin Veal (Apex, NC)
Assignee: Celgene Quanticel Research, Inc.
C07D401/04A61K31/00A61K31/444A61K31/4439A61K31/4545A61K31/4709A61K31/5377C07D401/14C07D405/14C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,701,657
App. No.
14/852,079
Granted
Jul 11, 2017
Kind
B2
Abstract

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

Claims (22)

1. A method for inhibiting a histone demethylase enzyme comprising contacting the histone demethylase enzyme with an effective amount of a compound of Formula (II):

wherein:

R 1 is hydrogen or C 6 -C 10 aryl optionally substituted with at least one hydroxy, hydroxyC 1 -C 5 alkyl, halogen, trihaloC 1 -C 5 alkyl, trihaloC 1 -C 5 alkoxy, trihaloC 1 -C 5 alkylaralkylamino, branched, straight chain, or cyclic C 1 -C 5 alkyl, C 2 -C 5 alkynyl, branched, straight or cyclic C 1 -C 5 alkoxy, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, C 3 -C 8 cycloalkyl(C 1 -C 5 alkyl), C 1 -C 5 alkylcarbamoyl, C 6 -C 10 aralkylcarbamoyl, or C 6 -C 10 aryl(C 1 -C 5 alkylene);

R 2 is C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, or C 6 -C 10 aryl, each of which is optionally substituted with branched, straight chain or cyclic C 1 -C 5 alkyl, C 1 -C 5 alkoxy or C 1 -C 5 alkamino, C 1 -C 5 alkylC 6 -C 10 aryl, diC 1 -C 5 alkylamino, diC 1 -C 5 alkylaminoalkoxy, (C 1 -C 5 alkylC 6 -C 10 aryl)(C 1 -C 5 alkyl)amino, C 1 -C 5 alkoxyaryl, C 6 -C 10 arylC 1 -C 5 alkyl, (C 6 -C 10 aryl)(C 1 -C 5 alkyl)amino, C 1 -C 5 alkylC 6 -C 10 aralkylamino, (C 6 -C 10 aralkyl)(C 1 -C 5 alkyl)amino, (C 3 -C 8 cycloalkyl)(C 1 -C 5 alkyl)amino, C 3 -C 8 cyclyl, napthalenyl, C 6 -C 10 arylC 6 -C 10 aryl, (C6-C 10 aryl(C 1 -C 5 alkylene))(C 1 -C 5 alkyl)amino, C 1 -C 5 alkylalkylaralkyl, haloC 6 -C 10 aryl, haloindenyl, trihaloC 1 -C 5 alkylaryl, dihaloC 6 -C 10 aralkylamino, haloC 6 -C 10 aralkylamino, trihaloC 1 -C 5 alkylC 6 -C 10 aralkamino, (haloaralkyl)(C 1 -C 5 alkyl)amino, C 1 -C 5 alkoxyC 6 -C 10 aralkylamino, or (C 3 -C 8 cyclolC 1 -C 5 alkyl)(C 1 -C 5 alkyl)amino;

R 3 is hydrogen; and

R 4 is —CO 2 H or —C(O)N(H)CN.

2. The method of claim 1 , wherein R 4 is —CO 2 H.

3. The method of claim 1 , wherein R 4 is —C(O)N(H)CN.

4. The method of claim 1 , wherein R 2 is C 1 -C 5 alkyl.

5. The method of claim 1 , wherein R 2 is methyl.

6. The method of claim 1 , wherein R 2 is C 1 -C 5 alkyl substituted with C 1 -C 5 alkoxy.

7. The method of claim 1 , wherein R 2 is C 1 -C 5 alkyl substituted with —N(C 1 -C 5 alkyl) 2 .

8. The method of claim 1 , wherein R 2 is C 1 -C 5 alkyl substituted with (C 6 -C 10 aryl)(C 1 -C 5 alkyl)amino.

9. The method of claim 1 , wherein R 2 is C 1 -C 5 alkyl substituted with (C 3 -C 8 cycloalkyl)(C 1 -C 5 alkyl)amino.

10. The method of claim 1 , wherein R 2 is C 1 -C 5 alkyl substituted with (C 6 -C 10 arylC 1 -C 5 alkyl)(C 1 -C 5 alkyl)amino, (C 1 -C 5 alkylC 6 -C 10 arylC 1 -C 5 alkyl)(C 1 -C 5 alkyl)amino, or (trihaloC 1 -C 5 alkylC 6 -C 10 arylC 1 -C 5 alkyl)(C 1 -C 5 alkyl)amino.

11. The method of claim 1 , wherein R 2 is C 1 -C 5 alkyl substituted with (C 3 -C 8 cycloalkylC 1 -C 5 alkyl)(C 1 -C 5 alkyl)amino.

12. The method of claim 1 , wherein R 1 is hydrogen.

13. The method of claim 1 , wherein R 1 is C 6 -C 10 aryl.

14. The method of claim 13 , wherein R 1 is phenyl substituted with at least one substituent selected from the group consisting of halogen, —OH, C 1 -C 5 alkyl, C 2 -C 5 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, C 3 -C 8 cycloalkylC 1 -C 5 alkylene, and C 6 -C 10 arylC 1 -C 5 alkyl.

15. The method of claim 10 , wherein R 2 is methyl(methylphenyl)methylamino.

16. The method of claim 10 , wherein R 2 is methyl(trifluoromethyl)phenylmethylamino.

17. The method of claim 10 , wherein R 2 is cyclopropyl(fluorophenyl)methylamino, ethyl(fluorophenyl)methylamino methyl(fluorophenyl)methylamino, or (fluorophenyl)methylamino.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2016
From: QUANTICEL PHARMACEUTICALS, INC.
To: CELGENE QUANTICEL RESEARCH, INC.
Reel/Frame 038399/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2015
From: KANOUNI, TOUFIKE; NIE, ZHE; STAFFORD, JEFFREY ALAN; VEAL, JAMES MARVIN
To: QUANTICEL PHARMACEUTICALS, INC.
Reel/Frame 036560/0461 →
Continuity (3)
Division 14210006 · Mar 13, 2014
Provisional Application 61783563 · Mar 14, 2013
Related Publication 20160113914A1 · Apr 28, 2016